Welcome!

News Feed Item

Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001

PHILADELPHIA, PA -- (Marketwired) -- 03/20/17 --


  • Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID)
    • Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo)
  • Clear signal of efficacy and benefit to patients
    • ADHD-RS response rate 70% (p=0.0067 vs placebo)
    • CGI-I response rate 57% (p=0.0155 vs placebo)
  • Well tolerated with no serious adverse events
  • Conference call scheduled for 8:30 AM ET

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced top-line results from the SAGA trial of AEVI-001 (oral non-stimulant) in adolescents with mGluR mutation positive (mGluR+) ADHD.

AEVI-001 represents a novel paradigm of genomic diagnosis and treatment in neuropsychiatric disorders. The mGluR predictive biomarker enabled study of AEVI-001 in an adolescent ADHD sub-population with genetic mutations that disrupt the mGluR network and result in glutamate imbalance.

Although AEVI-001 did not meet the primary endpoint of reduction on the ADHD rating scale (ADHD-RS) compared to placebo, there was an encouraging improvement observed on the inattention subscale (p=0.0515). Additionally, in a pre-specified responder analysis of ADHD-RS improvement of 30% or more, AEVI-001 demonstrated a statistically significant and clinically meaningful improvement compared to placebo. 70% of patients treated with AEVI-001 met this response definition versus 42% on placebo (p=0.0067).

In a second pre-specified responder analysis of Clinical Global Impression of Improvement scale (CGI-I), a key secondary endpoint, AEVI-001 demonstrated a statistically significant and clinically meaningful improvement compared to placebo. 57% of patients treated with AEVI-001 achieved a score of much improved or very much improved compared to 33% on placebo (p=0.0155).

The safety analysis demonstrated that AEVI-001 was well tolerated at all doses. The majority of adverse events were generally mild to moderate in severity and there were no serious adverse events.

"While we are disappointed that the SAGA trial did not achieve statistical significance on the primary endpoint of improvement on ADHD-RS, we are very encouraged by the clinically and statistically significant results we achieved on the ADHD-RS and CGI-I responder analyses," said Garry Neil, M.D., Chief Scientific Officer at Aevi Genomic Medicine. "There is a clear signal of efficacy and clinical benefit with AEVI-001 at the highest dose. The drug demonstrated a dose-response limited by the maximum dose of 400 mg BID and a favorable safety profile.

We remain committed to this program and our genomic approach, as we believe this is an important drug for patients with neuropsychiatric disorders. Moving forward we plan to explore higher doses, a refined genomic biomarker, and study pediatric patients which should enhance the response rates and effect size of AEVI-001. We look forward to discussing these results with the FDA and presenting the full data at the World Congress on ADHD in April."

"More than 20% of patients with ADHD have an mGluR mutation and current therapies unfortunately do not meet the significant needs of all patients" said Robert L. Findling, M.D., M.B.A., Principal Investigator of the SAGA trial, Vice President of Psychiatry Services and Research at Kennedy Krieger Institute and Professor of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine. "Although the SAGA trial did not meet its primary endpoint, the clinical results highlight a clear potential to benefit patients. I look forward to working with Aevi Genomics to better understand these results and further develop the molecule."

Conference Call Details

Aevi Genomics will host a conference call today to discuss the results of the SAGA trial on Monday, March 20, 2017 at 8:30 AM EDT. Mike Cola, CEO and Garry Neil, M.D., CSO will present the data, next steps in development of AEVI-001, and take questions.

In order to participate in the conference call, please dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international).

The live webcast can be accessed under "Events" in the Investors section of the Company's website at www.aevigenomics.com or you may use the link: https://services.choruscall.com/links/gnmx170321.html

A replay of the call will be available two hours after the end of the conference on March 20,2017 through June 20, 2017. To access the replay, please dial 877-344-7629 (domestic) or 412-317-0088 (international) and reference the conference ID number: 10103458.

The archived webcast will be available for 90 days in the Investor section of Aevi Genomic Medicine's website at www.aevigenomics.com.

We encourage participants to pre-register for the conference call using the following link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

To pre-register, go to: http://dpregister.com/10103458

About the SAGA Trial

The purpose of this multicenter, dose-optimized trial in adolescents with ADHD was to confirm the results from the Phase 1b GREAT study. The trial was designed as a randomized, double-blind, placebo-controlled, parallel-group study of AEVI-001 versus placebo in adolescent patients with ADHD who have genetic disorders impacting the mGluR network. The trial enrolled 101 patients (96 evaluable) between the ages of 12-17 years old. The primary and secondary endpoints in the trial were the change from baseline in the ADHD-Rating Scale Version 5 (ADHD-RS-5) Total Score and the percentage of subjects who responded as determined by the Clinical Global Impression of Improvement (CGI-I), respectively. Patients were randomized 1:1 to receive either a six-week course of AEVI-001 or placebo, with a one-week follow-up. Patients were enrolled from sites that participated in the recent phenotype/genotype study. More information on the SAGA trial is available at www.ClinicalTrials.gov (Identifier: NCT02777931).

AEVI-001 is an investigational agent that has not been approved by the U.S. FDA or any other regulatory agencies.

About AEVI-001

AEVI-001 is an oral non-stimulant pan selective activator/modulator of mGluRs. The molecule has excellent PK and metabolic profiles and crosses the blood brain barrier. In the Phase 1b GREAT trial, AEVI-001 demonstrated a strong efficacy signal in CGI-I and Vanderbilt rating scales in ADHD. There is significant human exposure as it was previously studied in vascular dementia by Nippon Shinyaku where the compound was shown to be safe and well tolerated.

Aevi Genomic Medicine is developing AEVI-001 as a potential treatment for a sub-population of ADHD patients with genetic mutations that disrupt the mGluR network and result in glutamate imbalance. Approximately 20 - 25% of pediatric ADHD patients are mGluR mutation positive thereby representing ~1.2 - 1.5 million patients eligible for treatment with AEVI-001.

The Company is exploring lifecycle opportunities for AEVI-001 for the treatment of patients with autism spectrum disorder (ASD) and pediatric generalize anxiety disorder (PGAD). In the US in 2012, 1 in 68 children were diagnosed with ASD (2012) increasing from 1 in 150 (2000)(8). There is a high unmet need for pharmaceutical treatments for ASD as currently approved medications are indicated for symptoms of irritability in ASD patients. Approximately 17% of the ASD population is mGluR+ patients(9). Approximately 3% of US children (3-17 years) have a current diagnosis of anxiety(10). There is similar unmet treatment need due to limited pharmacotherapy options. Approximately 13% of pediatric anxiety patients are mGluR+ patients(9).

About ADHD

In the United States, the CDC estimates that 6.4 million children 4-17 years of age (11%) have ever been diagnosed with ADHD.(1) ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood(2).

DSM-V defines ADHD as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.(3) ADHD causes significant impairment in childhood and throughout the lifespan(4), as well as increased mortality and psychosocial adversity(5). There is no definitive management for ADHD; current management frequently includes a combination of educational support, behavioral interventions, and pharmacotherapy. Current standard of care is the stimulant class of medications including immediate- and extended-release methylphenidate and amphetamine; these products represent 90% of sales in the U.S. ADHD market(6). In 2016, U.S. ADHD pharmaceutical product sales were $11B growing at a compounded annual growth rate of ~2% from 2012 to 2016(6). However, while conferring benefit for many patients, currently available ADHD medications also have significant limitations including decreased appetite, weight loss, insomnia(7).

About the ADHD-RS-5 and CGI-I Scale

The ADHD-RS-5 is a parent reported/clinician-rated scale that was developed to measure the behaviors of children with ADHD, with separate forms for children (ages 5-10 years) and adolescents (11-17 years). The scale consists of 18 items designed to reflect the symptomatology of ADHD based on the Diagnostic and Statistics Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.

Two scales are used to capture the clinician's global assessment. The CGI-I is an assessment of improvement in symptoms, relative to baseline and is based on reports from parents, subjects, and minimal direct observation. Scoring ranges from 1 (very much improved) to 7 (very much worse). The CGI-S scale is used to rate the severity of a subject's condition on a 7-point scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill subjects).

About Aevi Genomic Medicine, Inc.

Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverages an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP).

In addition to the AEVI-001 programs, we are also progressing our second program, AEVI-002 into clinical development for Severe Pediatric Onset Crohn's Disease.

More information on the company and pipeline is located on our website www.aevigenomics.com

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

Sources
(1)https://www.cdc.gov/ncbddd/adhd/data.html
(2)https://www.cdc.gov/ncbddd/adhd/facts.html
(3)https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml
(4)Barkley RA, Fischer M, Smallish L, Fletcher K. (2006) Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 45(2):192-202.
(5)Barbaresi WJ, Colligan RC, Weaver AL, Voigt RG, Killian JM, Katusic SK. (2013) Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics. 131(4):637-44.
(6)IMS NSP
(7)Elia J, Kingsley K, Lam C, Takeda T, de Berardinis R, Laracy S, et al. (2013) Pharmacological treatment and prognosis of ADHD. In: ADHD: Clinical Management of Attention Deficit Hyperactivity Disorder. London, UK: Future Medicine LTD. 73-102.
(8)https://www.cdc.gov/ncbddd/autism/data.html
(9)Data on file, H. Hakonarson
(10)ttps://www.cdc.gov/childrensmentalhealth/data.html

CONTACT:

Aevi Genomic Medicine, Inc.
Brian Piper
Email Contact

Westwicke Partners
Chris Brinzey
+1-339-970-2843
Email Contact

MEDIA INQUIRIES:

FTI Consulting
Irma Gomez-Dib
+1-212-850-5761
+1-415-706-9155
http://Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
"Digital transformation - what we knew about it in the past has been redefined. Automation is going to play such a huge role in that because the culture, the technology, and the business operations are being shifted now," stated Brian Boeggeman, VP of Alliances & Partnerships at Ayehu, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
Sanjeev Sharma Joins June 5-7, 2018 @DevOpsSummit at @Cloud Expo New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...